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Background: Endothelial nitric oxide synthase (eNOS)
could be a candidate gene for coronary artery disease
(CAD). This study investigated the relationship of the
eNOS Glu2983Asp and T7863C polymorphisms with
the presence and severity of CAD in the Italian popula-
tion.
Methods: We enrolled 415 unrelated individuals who
underwent coronary angiography. The severity of CAD
was expressed by means of the Duke score. The eNOS
Glu2983Asp and T7863C variants were analyzed by
PCR.
Results: There was significant linkage disequilibrium
between the two eNOS polymorphisms (P <0.0001).
Both variants were significantly associated with the
occurrence and severity of CAD (P  0.01 and 0.004 for
Glu2983Asp and T7863C, respectively). The risk of
CAD was increased among individuals homozygous for
the C allele of the T7863C polymorphism compared
with individuals homozygous for the T allele (odds
ratio  2.5; P <0.01) and was independent of the other
common risk factors (P  0.04). Moreover, individuals
with both the Asp/Asp genotype of the Glu2983Asp
polymorphism and at least one C allele of the T7863C
variant in the promoter region of the eNOS gene had an
increased risk of CAD (odds ratio  4.0; P <0.001) and a
significantly higher mean Duke score (26.2  2.9 vs
45.2  3.7; P  0.002) compared with individuals with
the TT genotype and the Glu allele.
Conclusions: The present study provides evidence that
the Glu2983Asp and T7863C polymorphisms of the
eNOS gene are associated with the presence and sever-
ity of angiographically defined CAD in the Italian
population and that those individuals carrying both
eNOS variants simultaneously might have a higher risk
of developing CAD.
© 2003 American Association for Clinical Chemistry
In the vascular endothelium, NO, a powerful short-lived
vasoactive substance, is constitutively produced from
l-arginine by the enzyme endothelial nitric oxide syn-
thase (eNOS)1 (1 ). NO plays a key role in the relaxation of
vascular smooth muscle, inhibits adhesion of platelets and
leukocytes to the endothelium, reduces vascular smooth
muscle cells migration and proliferation, and limits the
oxidation of atherogenic low-density lipoproteins (2 ).
Moreover, it has been shown that eNOS inhibition accel-
erates atherosclerosis in animal models and that abnor-
malities in the endothelial NO pathway are present in
humans with atherosclerosis (3, 4).
This evidence suggests that NO may inhibit several key
steps in the atherosclerotic process and that an alteration
of NO production within the vascular endothelium could
contribute to the pathogenesis of atherosclerosis. There-
fore, functionally important variants of the eNOS gene
could influence individual susceptibility to atherosclero-
sis by altering the amount of NO generated by the
endothelium.
Several polymorphisms have been identified in the
eNOS gene. Among them, a common variant located in
exon 7 (G9843T) of the eNOS gene that modifies its
coding sequence (Glu2983Asp) has been linked by sev-
eral groups to the risk for coronary spasm, coronary
artery disease (CAD), and acute myocardial infarction
(5–8). We have also previously reported that the
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Glu2983Asp polymorphism is associated with the occur-
rence and severity of CAD in the Italian population (9 ).
On the other hand, other studies failed to find any
relationship between the Asp variant and the risk of
atherosclerosis, suggesting that the Asp allele may act
merely as a marker for a functional mutation in either
eNOS or a nearby gene (10–12).
Recently, a polymorphism in the 5-flanking region of
the eNOS gene (T7863C) that affects eNOS expression has
been associated with coronary spasm among Japanese
(13 ). Although this finding relates to a condition of low
prevalence outside Japan, it has wide-ranging implica-
tions because it suggests a link between decreased endo-
thelial NO production as a result of the eNOS T7863C
variant and vascular disease (14, 15).
In the present study, we investigated the associations
between the occurrence and severity of angiographically
defined CAD and the T7863C polymorphism in the
5-flanking region of the eNOS gene alone and in combi-
nation with the Glu2983Asp polymorphism.
Materials and Methods
study population
We studied 268 patients consecutively admitted to our
institute who had angiographically defined CAD (50%
stenosis affecting at least one coronary vessel; CAD cases)
and 147 individuals recruited from patients admitted for
valve replacement, in whom angiographic examination
excluded the presence of CAD (controls). Controls were
enrolled providing that they had neither a history nor
clinical or instrumental evidence of atherosclerosis in
peripheral vascular districts. Individuals with coronary
spastic angina in the absence of luminal atheroma were
not enrolled in the study. All patients and controls were
from the Italian population.
All participants were interviewed, and data on smok-
ing habits, hypertension, diabetes, dyslipidemia, and fam-
ily history of CAD were recorded. Informed consent was
obtained from all patients and controls according to the
guidelines of our ethics committee. For coronary risk
factors, the following definitions were used: individuals
were defined as hypertensive if their blood pressure was
140/90 mmHg or if they were receiving any antihyper-
tensive treatment; individuals with a history of diabetes
or those receiving any antidiabetic medication were con-
sidered to be diabetic; individuals were deemed dyslipi-
demic when their total cholesterol concentration was
2200 mg/L, their triglyceride concentration was 2000
mg/L, or they were receiving lipid-lowering drugs.
Smoking history was coded as never, ex-smoker (at least
6 months), and current smoker. The family history was
considered positive for CAD if at least one first-degree
male relative was diagnosed with CAD by the age of 55 or
one first-degree female relative was diagnosed with CAD
by the age of 65 years.
angiographic study
All participants underwent coronary angiography. Coro-
nary stenosis was considered significant if the luminal
diameter of at least one epicardial coronary artery was
narrowed by 50%. The extent and the severity of CAD
were evaluated by means of the Duke scoring system (16 ).
This CAD prognostic index considers the number of
diseased major vessels as well as left main coronary artery
disease, the percentage of narrowing of the major vessels,
and involvement of the left anterior descending coronary
artery, particularly when the proximal segment shows
severe stenosis (95%). Duke scores range from 0 to 100
(0  no disease; 100  most severe disease).
analysis of Glu2983Asp polymorphism in exon 7
of the eNOS gene
Genomic DNA was extracted from samples of whole
blood by standard methods (17 ). The Glu2983Asp poly-
morphism was a G3T substitution at nucleotide position
894 in exon 7 that encodes for replacement of glutamic
acid by aspartic acid at residue 298 in the mature eNOS
protein. Genotyping of all participants was by PCR am-
plification of exon 7 with the primers 5-CATGAGGCT-
CAGCCCCAGAAC-3 (sense) and 5-AGTCAATCCCTT-
TGGTGCTCAC-3 (antisense) followed by MboI
restriction enzyme digestion for 16 h at 37 °C. In the
presence of a T at nucleotide 894, which corresponds to
Asp298, the 206-bp PCR product is cleaved into two
fragments of 119 and 87 bp. The products of the digestion
process were separated by electrophoresis on a 1.5%
agarose gel and visualized by ethidium bromide staining.
analysis of T7863C polymorphism in the 5-
flanking region of the eNOS gene
The presence of the T3C conversion at nucleotide posi-
tion 786 in the 5-flanking region of the eNOS gene was
determined by PCR amplification with the primers 5-
ATGCTCCCACCAGGGCATCA-3 (sense) and 5-GTC-
CTTGAGTCTGACATTAGGG-3 (antisense). The 236-bp
PCR fragments were digested with NgOAIV restriction
enzyme for 16 h at 37 °C. The wild-type allele (T) has no
NgOAIV cleavage site, whereas the PCR product is
cleaved into two fragments of 203 and 33 bp in the
presence of the C786 allele.
statistical analysis
All statistical analyses were conducted with use of the
Statview statistical package, Ver. 5.0.1 (SAS Institute).
Data are expressed as the mean (SE). Differences between
the means of the two continuous variables were evaluated
by Student t-test. Differences between noncontinuous
variables, genotype distribution, and Hardy–Weinberg
equilibrium were tested by 2 analysis. Linkage disequi-
librium between the two polymorphisms was examined
by 2 analysis. The extent of disequilibrium was ex-
pressed as: D  D/Dmax (18 ). One-way ANOVA was
used to analyze the relationships between genotypes and
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the general characteristics and severity of CAD in terms of
Duke score. Logistic regression analysis was used to
assess the independent effect of each risk factor on the
occurrence of CAD. The interaction between the eNOS
Glu2983Asp and T7863C genotypes on CAD risk was
evaluated by adding the new product variable
(Glu2983Asp genotype)  (T7863C genotype) in the
logistic regression model. P 0.05 was considered statis-
tically significant.
Results
comparison of the two study groups
The demographic and clinical characteristics of the study
groups are shown in Table 1. The prevalence of athero-
genic risk factors (age, sex, hypertension, diabetes, dys-
lipidemia, cigarette smoking, and family history of CAD)
was significantly higher in the group of CAD patient.
relationship between the Glu2983Asp and
T7863C polymorphisms of the eNOS gene
The relationship between the Glu2983Asp and T7863C
polymorphisms of the eNOS gene was assessed in 374
genotyped individuals. Comparison of allele and haplo-
type frequencies revealed that the eNOS Asp298 allele was
weakly (D  0.38) but significantly linked to the T7863C
polymorphism in the 5-flanking region of the eNOS gene
because the Asp298 allele was preferentially found in a
subgroup of individuals with at least one C786 allele
(Table 2; P 0.0001).
association of Glu2983Asp and T7863C
polymorphisms of the eNOS gene with cad
The distributions of the Glu2983Asp genotypes in both
CAD cases and controls satisfied the Hardy–Weinberg
equilibrium. In agreement with our previous report (9 ),
we confirmed that the Glu2983Asp polymorphism in
exon 7 of the eNOS gene was significantly associated with
the presence of CAD in this expanded sample size [total
study population of 415 vs 315 in the previous report (9 );
Table 3; P  0.03].
As for the Glu2983Asp variant, the T7863C polymor-
phism in the 5-flanking region of the eNOS gene was
significantly associated with the presence of CAD in our
patients as well (Table 3; P  0.02). In fact, the proportion
of C786 homozygotes was 24.6% in the CAD cases com-
pared with 14.5% in controls. These frequencies were in
agreement with those predicted by Hardy–Weinberg
equilibrium.
Compared with T786 homozygotes, the odds ratio (OR)
for CAD associated with the CC786 genotype was 2.5 (P
0.01), whereas TC786 carriers had a slightly but not
significantly increased risk of CAD (Table 4). Moreover,
multivariate analysis showed that the CC786 genotype was
an independent risk factor for CAD (Table 5).
We also investigated a possible synergistic effect be-
tween the Glu2983Asp and T7863C polymorphisms of
the eNOS gene (Table 6). When we evaluated the risk
associated with the eNOS T7863C variant alone, we
found that among carriers of the Glu allele of the
Glu2983Asp polymorphism, individuals with at least one
Table 1. Demographic and clinical characteristics of the
study population.
CAD cases
(n  268)
Controls
(n  147) P
Mean (SE) age, years 60.8 (0.6) 53.5 (1.2) 0.0001
Male sex, n (%) 228 (85.1) 73 (49.7) 0.0001
Hypertension, n (%) 162 (60.4) 37 (25.2) 0.0001
Diabetes, n (%) 60 (22.5) 7 (4.8) 0.0001
Dyslipidemia, n (%) 175 (65.3) 26 (17.7) 0.0001
Smoking status
Never smoked, n (%) 109 (40.7) 102 (69.4) 0.0001
Ex-smokers, n (%) 107 (39.9) 29 (19.7)
Current smokers, n (%) 52 (19.4) 16 (10.9)
Family history of CAD, n (%) 117 (43.7) 28 (19) 0.0001
Number of diseased vessels
One vessel, n 102
Two vessels, n 92
Three vessels, n 74
Table 2. Relationship between the Glu2983Asp and
T7863C polymorphisms of the eNOS gene.a
Glu2983Asp genotype
T7863C genotype
TT TC CC Total
Glu/Glu 72 72 12 156
Glu/Asp 24 108 33 165
Asp/Asp 5 15 33 53
Total 101 195 78 374
aP 0.0001 for all.
Table 3. Genotype and allele frequencies of Glu2983Asp
and T7863C polymorphisms of the eNOS gene in
angiographically defined CAD cases and controls.
CAD cases Controls P
Glu2983Asp polymorphism 0.03
Glu/Glu, n (%) 109 (40.7) 65 (44.2)
Glu/Asp, n (%) 116 (43.3) 72 (49)
Asp/Asp, n (%) 43 (16.0) 10 (6.8)
Total 268 147
Allele 0.06
Glu, n (%) 334 (62.3) 202 (68.7)
Asp, n (%) 202 (37.7) 92 (31.3)
Total 536 294
T7863C polymorphism 0.02
TT, n (%) 54 (22.9) 47 (34.1)
TC, n (%) 124 (52.5) 71 (51.4)
CC, n (%) 58 (24.6) 20 (14.5)
Total 236 138
Allele 0.01
T, n (%) 232 (49) 165 (60)
C, n (%) 240 (51) 111 (40)
Total 472 276
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C786 allele were at higher risk of CAD than carriers of the
TT genotype in the promoter region of the eNOS gene
(OR  1.6; P  0.05). Moreover, compared with individ-
uals who were carriers of the Glu allele and TT genotype
simultaneously, the OR for CAD associated with the
presence of both the Asp/Asp genotype of the
Glu2983Asp polymorphism and at least one C allele of
the T7863C polymorphism was 4.0 (P 0.001). Further-
more, we found that among individuals homozygous for
the T786 allele of the promoter variant of the eNOS gene,
the presence of Asp/Asp genotype conferred an increased
risk for CAD (OR  3.6), although it failed to reach
statistical significance, probably because of the small
number of carriers of Asp/Asp plus TT (n  5; Table 2).
In fact, for carriers of the C786 allele of the eNOS promoter
polymorphism, the OR for CAD associated with the
Asp/Asp genotype of the Glu2983Asp polymorphism
was significantly increased compared with those individ-
uals with at least one Glu allele (OR  2.2; P  0.03).
Glu2983Asp and T7863C polymorphisms of the
eNOS gene and severity of cad
The relationships between several variables and the
Glu2983Asp and T7863C genotypes were studied in all
participants. We found no association between both eNOS
polymorphisms and sex, hypertension, dyslipidemia, di-
abetes, smoking status, and family history of CAD (data
not shown).
Of note was that the presence of the eNOS T7863C
allele was significantly associated with the extent and
severity of CAD evaluated by means of the Duke scoring
system (39.6  2.9, 38.1  2.2, and 27.3  2.8 for CC786,
TC786, and TT786, respectively; P  0.004; Fig. 1).
Moreover, as we have shown previously (9 ), the mean
Duke score was higher for individuals homozygous for
the Asp/Asp genotype of the Glu2983Asp polymor-
phism than for Glu/Glu and Glu/Asp carriers (44.7  3.5
for Asp/Asp vs 34.5 1.5 for Glu allele carriers; P 0.01).
We also evaluated the potential interaction between
both eNOS gene polymorphisms and the extent and
severity of CAD in the total population (Fig. 2). Among
carriers of the Glu allele for the Glu2983Asp polymor-
phism, individuals with at least one C allele of the eNOS
T7863C variant had a significantly higher mean CAD
Duke score than individuals with the TT genotype (37.2
1.9 vs 26.2 2.9; P 0.02). Moreover, the severity of CAD
was significantly associated with the presence of both the
Asp/Asp genotype of the Glu2983Asp polymorphism
and at least one C allele of the T7863C polymorphism
(Duke score, 45.2  3.7 vs 26.2  2.9 for Asp/Asp
genotype and C allele compared with Glu allele and TT
genotype, respectively; P  0.002). However, among
carriers of the C allele of the T7863C variant, those who
were also homozygous for the Asp allele of the
Glu2983Asp polymorphism showed a slightly but not
significant increase in the severity of CAD with respect to
Glu allele carriers (Duke score, 45.2  3.7 vs 37.2  1.9;
P  0.1).
Discussion
This study investigated the relationship between the
eNOS Glu2983Asp and T7863C polymorphisms and the
presence and severity of CAD and searched for potential
interactions between these gene variations and the risk of
CAD.
distributions of the Glu2983Asp and T7863C
variants of the eNOS gene
According to our previous report, the Glu2983Asp poly-
morphism in exon 7 of the eNOS gene is significantly
associated with the presence of CAD (9 ). Moreover, we
reported the association between the common T7863C
polymorphism in the 5-flanking region of the eNOS gene
and the occurrence of CAD in the Italian population.
Indeed, we found an excess of homozygosity for the C786
variant among CAD cases compared with controls (24.6%
vs 14.5%), and these genotype frequencies were in agree-
ment with those recently reported by Ghilardi et al. (19 )
among Italian individuals with moderate to severe inter-
nal carotid artery stenosis and healthy controls. The risk
of developing CAD was 2.5-fold higher for C786 homozy-
gotes with respect to individuals who were homozygous
for the T786 allele in the eNOS gene promoter. Multivari-
ate analysis demonstrated that this association was inde-
pendent of other factors possibly related to CAD risk.
genetic linkage between the T7863C and
Glu2983Asp polymorphisms of the eNOS gene
Among many polymorphisms of the eNOS gene, it has
become clear that the intron 4b/a, the Glu2983Asp, and
Table 4. OR for CAD among carriers of the T7863C and
Glu2983Asp variants.
Genotype Reference group OR (95% CI)a P
CC TT 2.5 (1.3–4.8) 0.01
TC TT 1.5 (0.9–2.4) 0.13
CC  TC TT 1.7 (1.1–2.8) 0.02
Asp/Asp Glu/GluGlu/Asp 2.6 (1.3–5.4) 0.01
aCI, confidence interval.
Table 5. Relative risk of CAD by coronary risk factors and
by T7863C polymorphism of the eNOS gene.
Risk factors Relative risk (95% CI)a P
Age 1.0 (1.0–1.1) 0.97
Male sex 4.0 (1.4–11.2) 0.01
Smoke 3.3 (0.9–12) 0.06
Hypertension 4.5 (1.7–11.9) 0.01
Diabetes 8.6 (1.5–47.8) 0.01
Dyslipidemia 6.1 (2.4–15.6) 0.0001
Family history of CAD 2.6 (1.0–7.1) 0.05
CC vs TT genotypes 2.7 (1.0–7.0) 0.04
aCI, confidence interval.
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the T7863C variants have important implications in car-
diovascular diseases (5, 6, 13, 20, 21). The intronic poly-
morphism, which has been reported to be involved in a
smoking-dependent risk for CAD, is less likely to have a
functional role per se than either the promoter or coding
region variants, but it may act as a marker for potentially
functional variants elsewhere in the gene (20 ). Indeed,
Yoshimura et al. (22 ) first reported that the intron 4b/a
polymorphism is in linkage disequilibrium with the eNOS
T7863C variant, suggesting that the T7863C mutation
underlies the functional characteristics of the intron 4a
allele, whereas they found no relationship between the
Glu2983Asp and T7863C variants. In contrast, Alvarez et
al. (23 ) failed to confirm this previously described genetic
linkage; they found that the CC786 genotype conferred an
increased risk of an early episode of CAD in a Caucasian
population but that the 4b/a polymorphism did not.
Furthermore, another association study between genetic
polymorphisms of the eNOS gene and hypertension in
Japanese has recently shown that the T7863C polymor-
phism is significantly linked to the Glu2983Asp polymor-
phism with trans configuration (the T786 allele is linked to
the Asp298 and the C786 allele to the Glu298) (24 ).
In this study we found that the Asp298 allele is weakly
but significantly linked to the C786 allele of the T7863C
polymorphism in the 5-flanking region of the eNOS gene;
this evidence is in agreement with that recently reported
in another European population in terms of both extent of
disequilibrium and allele frequency (25 ).
functional significance of the T7863C and
Glu2983Asp polymorphisms of the eNOS gene
We and others have previously reported that the risk for
CAD is confined to individuals homozygous for the Asp
allele of the Glu2983Asp polymorphism, suggesting that
homozygosity for aspartic acid in position 298 could
produce a significant decrease in the amount of eNOS or
its enzymatic activity (6, 9). Indeed, it has recently been
shown that the eNOS Asp298 protein has enhanced sus-
ceptibility to intracellular proteolytic cleavage compared
with the eNOS Glu298 protein (26 ). Another possible
explanation for the association of the Glu2983Asp poly-
morphism with the risk of CAD is that the Asp298 allele is
in linkage disequilibrium with other functional variants
within the eNOS or another gene.
In the present study, we found that the Asp298 allele is
in linkage disequilibrium with the C786 variant in the
promoter region of the eNOS gene; it is not known,
however, whether the T7863C polymorphism underlies
the functional characteristic of the Asp298 allele. Indeed, in
our population, carriers of both Asp/Asp and at least one
C786 allele were at higher risk of CAD than carriers of
single genotypes, suggesting the possibility of a synergis-
tic effect between the Glu2983Asp and T7863C polymor-
phisms of the eNOS gene on CAD risk.
The T7863C mutation in the 5-flanking region of the
eNOS gene was originally reported by Nakayama et al.
(13 ) in patients with coronary vasospasm. Importantly,
they found that the T7863C mutation decreased promoter
activity by 50%, suggesting that in many carriers of the
mutant allele, the l-arginine/NO pathway does not func-
tion properly, leading to endothelial dysfunction.
It is well accepted that endothelial dysfunction occurs
in response to cardiovascular risk factors and precedes the
development of atherosclerosis (27, 28). Thus, it is possi-
Fig. 1. T7863C polymorphism of eNOS gene and severity of CAD.
, P  0.004, TT vs TC or CC genotype. Error bars, SE.
Fig. 2. Severity of CAD in individuals with different combinations of the
eNOS T7863C and Glu2983Asp polymorphisms.
, P  0.02 vs simultaneous carriers of Glu and C alleles; †, P  0.002 vs
simultaneous carriers of Asp/Asp genotype and C allele. Error bars, SE.
Table 6. OR for CAD among combination of the Glu2983Asp and T7863C variants.
Genotypes Reference group OR (95% CI)a P
(Glu/Glu or Glu/Asp)*(CC or TC) (Glu/Glu or Glu/Asp)*TT 1.6 (1–2.6) 0.05
Asp/Asp*(CC or TC) (Glu/Glu or Glu/Asp)*TT 4.0 (1.7–9.1) 0.001
Asp/Asp*TT (Glu/Glu or Glu/Asp)*TT 3.6 (0.4–33.4) 0.21
Asp/Asp*(CC or TC) (Glu/Glu or Glu/Asp)*(CC or TC) 2.2 (1–4.7) 0.03
aCI, confidence interval.
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ble that the T7863C mutation in the 5-flanking region of
the eNOS gene, which affects promoter activity and
endothelial synthesis of NO, and the Glu2983Asp poly-
morphism may make carriers susceptible to the develop-
ment of endothelial dysfunction and in turn to CAD (29 ).
Moreover, it is noteworthy that we observed an asso-
ciation between the T7863C polymorphism and the Duke
scoring system, a prognostic index that considers not only
the number of stenosed vessels but also the percentage of
narrowing of the major vessels and the anatomical local-
ization of the stenosis. Consequently, our data suggested
the possibility that in the process of atherosclerotic re-
modeling of adult human vessels, alterations in NO
production resulting from the C786 defect in the promoter
region of the eNOS gene could have great impact on
smooth muscle cell migration and proliferation. This
hypothesis should be tested but is supported by in vivo
evidence that eNOS-mutant mice displayed a paradoxical
increase in wall thickness, accompanied by a hyperplastic
response of the arterial wall in response to carotid artery
ligation, indicating that a primary defect in the NOS/NO
pathway may promote abnormal remodeling and patho-
logic changes in vessel wall morphology associated with
atherosclerosis (30 ).
In conclusion, the present study provides evidence that
the Glu2983Asp and T7863C polymorphisms of the
eNOS gene are associated with the presence, extent, and
severity of angiographically defined CAD in the Italian
population and that those individuals with both eNOS
polymorphisms simultaneously might have a higher risk
of developing CAD. However, it has recently been re-
ported that neither Glu2983Asp nor T7863C polymor-
phisms significantly influenced plasma nitrate/nitrite
concentrations and the risk of ischemic heart disease in a
large cohort of middle-aged British men (25 ). Therefore,
further studies are needed to investigate whether the
Glu2983Asp and T7863C polymorphisms of the eNOS
gene could represent useful genetic markers for identify-
ing individuals at risk for the development of CAD. In
particular, it is necessary to explore and clarify the puta-
tive effects of the Glu2983Asp and T7863C polymor-
phisms both alone and in combination on the endothelial
NO function and their significance in terms of risk for
atherosclerosis-related disease in different populations.
Finally, prospective studies are needed to determine how
predictive the eNOS variants are for new onset of CAD.
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